167 related articles for article (PubMed ID: 38454486)
1. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.
Nakamura K; Sakai N; Hossain MA; Eisengart JB; Yamamoto T; Tanizawa K; So S; Schmidt M; Sato Y
Orphanet J Rare Dis; 2024 Mar; 19(1):104. PubMed ID: 38454486
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO
Yamamoto R; Kawashima S
Nihon Yakurigaku Zasshi; 2022; 157(1):62-75. PubMed ID: 34980815
[TBL] [Abstract][Full Text] [Related]
3. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
Giugliani R; Martins AM; Okuyama T; Eto Y; Sakai N; Nakamura K; Morimoto H; Minami K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681597
[TBL] [Abstract][Full Text] [Related]
4. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
[TBL] [Abstract][Full Text] [Related]
5. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
Okuyama T; Eto Y; Sakai N; Nakamura K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Sato Y
Mol Ther; 2021 Feb; 29(2):671-679. PubMed ID: 33038326
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Yamamoto R; Yoden E; Tanaka N; Kinoshita M; Imakiire A; Hirato T; Minami K
Mol Genet Metab Rep; 2021 Jun; 27():100758. PubMed ID: 33981582
[TBL] [Abstract][Full Text] [Related]
8. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
Imakiire A; Morimoto H; Suzuki H; Masuda T; Yoden E; Inoue A; Morioka H; Konaka T; Mori A; Shirasaka R; Kato R; Hirato T; Sonoda H; Minami K
Mol Pharm; 2023 Nov; 20(11):5901-5909. PubMed ID: 37860991
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
[TBL] [Abstract][Full Text] [Related]
10. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
13. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
Ueda K; Hokugo J
Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
[TBL] [Abstract][Full Text] [Related]
15. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
[TBL] [Abstract][Full Text] [Related]
16. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
Tomita K; Okamoto S; Seto T; Hamazaki T; So S; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
JIMD Rep; 2021 Nov; 62(1):9-14. PubMed ID: 34765392
[TBL] [Abstract][Full Text] [Related]
17. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
